



August 3, 2021

Investor Presentation

Forward Looking Statements

This presentation contains forward-looking statements with the meaning of the Private Securities Litigation Reform Act. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies, plans and prospects. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this presentation when we discuss Indaptus's future plans and expected timeline of its development pipeline.

Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: Indaptus's plans to develop and potentially commercialize its technology; the timing and cost of Indaptus's planned investigational new drug application and any clinical trials; the completion and receiving favorable results in any clinical trials; Indaptus's ability to obtain and maintain regulatory approval of any product candidate; Indaptus's ability to protect and maintain its intellectual property and licensing arrangements; Indaptus's ability to develop, manufacture and commercialize its product candidates; the risk of product liability claims; the availability of reimbursement; the influence of extensive and costly government regulation; and Indaptus's estimates regarding future revenue, expenses, capital requirements and the need for additional financing following the merger. These risks, as well as other risks are discussed in the proxy statement/prospectus that was included in the registration statement on Form S-4 filed with the SEC in connection with the merger.

All forward-looking statements speak only as of the date of this presentation and are expressly qualified in their entirety by the cautionary statements included in this presentation. Indaptus does not undertake any obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

The presentation contains information about investigation-stage drug products under development, which have not yet been approved by the FDA for commercial distribution in the United States. All representations in this presentation are based upon investigations in certain clinical and other research, but which accordingly should not be construed as general claims for the safety or efficacy of the products when used by patients.

The presentation is not intended and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Indaptus Therapeutics

With the ability to harness both the body's innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases.



Broad Platform

- Immunology-based anti-tumor & anti-viral platform with a wide therapeutic index
- Oncology, HBV, HIV activity



Safety

- Attenuation and passive targeting reduces systemic exposure and toxicity
- IND-enabling toxicology indicates no induction of cytokine release syndrome



Efficacy

- Synergistic with checkpoint therapy, targeted antibodies or chemotherapy
- 80 to 100% complete responses in multiple mouse and human tumor models



CMC

- Tech transfer & scale up processes completed - GMP material manufactured
- Clinical product released and stable for 6 months under multiple conditions



IP


- Composition of matter (NCE), methods of making and methods of using patents granted
- Patent estate runs through 2039



Inflection Timeline

- US FDA Pre-IND meeting completed / IND filing anticipated 2H '21
- Phase 1 initiation anticipated 1H '22

Current Cancer Immunotherapies: Low Percentage Cures for Most Advanced Cancers




Current immunotherapies only cure a very small percentage of advanced cancer patients, because they activate only one or a few innate or adaptive immune cell types

Improving Cancer Immunotherapy - Indaptus Assumptions

- **We need innate & adaptive pathway activation in lymphoid organs as well as tumor**
 - Tumors promote an immune-suppressive environment
 - Tumors negatively remodel the entire systemic immune system
 - Most steps required for innate and adaptive immune responses take place outside of the tumor

Goal is Activation of Both Innate and Adaptive Cellular Pathways in Multiple Locations



World's First Immunotherapy: Clinically Validated and Composed of Killed Bacteria

- **Coley's Toxins (CT) – based on observation of regression of cancer in setting of infection**
 - Invented by Dr. William Coley at Memorial Sloan Kettering in NYC in 1894
 - Composed of heat-killed bacteria
- **Coley's Toxins produced durable responses with several hundred advanced cancer patients**
 - Associated with induction of fever by killed, Gram-negative bacteria

<https://www.cancerresearch.org/about-cri/cri-history>

<https://www.mskcc.org/blog/immunotherapy-revolutionizing-cancer-treatment-1891>
- **Coley's Toxins worked best i.v., but were too toxic, so given i.t. and s.c.**
 - i.t. and s.c. administration produced highly variable results

Immunological Sciences Caught Up to the Clinic in the 1990's

Bacteria Contain Immune System Stimulating Danger Signals

- **The most prominent danger signal family activates Toll-like receptors (TLR)**

<u>Source</u>	<u>Danger Signal (TLR Ligand / Agonist)</u>	<u>Toll-Like Receptor</u>
Bacteria	Lipoproteins, Peptidoglycans	TLR2 (1/2, 6/2)
Viruses (Bacteria?)	Double Stranded RNA	TLR3
Bacteria	Lipopolysaccharide (LPS / endotoxin)	TLR4
Bacteria	Flagellin	TLR5
Viruses (Bacteria?)	Single Stranded RNA	TLR7/8
Bacteria	Unmethylated CpG DNA	TLR9

- **TLRs directly and indirectly activate essentially all immune cells (innate + adaptive)**
 - Indirect activation occurs via induction of secretion of cytokines and chemokines
- **Cytokines and chemokines are principal inducers of anti-tumor immune responses**
 - Innate - cell recruitment, MΦ activation, NK cell activation, $\gamma\delta$ T-cell activation, $\downarrow$ Treg
 - Adaptive - cell recruitment, APC/DC activation, T-cell activation ($CD4_H/CD8_{CTL}$), $\downarrow$ Treg

Indaptus has Used Modern Science to Optimize and Re-Invent the Approach

Decoy Product

- Start with a single, pure strain of non-pathogenic, Gram-negative bacteria
- Reduce LPS-endotoxin level by ~90%
- Kill the bacteria and stabilize so they remain intact after i.v. administration
- Product is a frozen suspension of killed, intact bacteria
- Chemical modification yields NCE
Broad patent coverage: CoM + Methods
4 issued US & 27 issued foreign patents
Additional world-wide applications
Nominal expiry – 2 families 2033/2039



Result and Predictions

- Decoy therapeutic is significantly less toxic *in vivo* than untreated bacteria and several live competitor products
- i.v. bacteria are passively targeted to liver, spleen and tumors, and cleared rapidly
- Predict “Goldilocks” effect:
 - Immune activation better than with i.t. dosing: Critical activation in spleen and can target primary liver cancer and liver metastasis from other tumors
 - Passive targeting and rapid clearance precludes continuous, systemic exposure common to small molecule, antibody and CAR therapies:
Reduced chance of systemic toxicity

Indaptus Result – Effective, Safe and Patented

Decoy therapeutics exhibit many unique properties

- Single agent anti-tumor activity + tumor eradicating synergy with 5 different existing therapies
- Reduced toxicity and broad therapeutic index (no increase in toxicity with combinations)
- Safe induction of both innate and adaptive immune pathways (MoA) confirmed
- Innate and adaptive immunological memory leading to rejection of tumor re-challenge
- Efficacy in mouse syngeneic and human tumor xenograft models (CRC, HCC, Pancreatic, NHL)
- GMP batch of drug product produced (Decoy20) – stable for ≥6 months at -70°C, -20°C and 5°C
- IND-enabling toxicology with GMP drug product – no induction of cytokine release syndrome
- Significant single agent activity in pre-clinical models of HBV and HIV

Decoy Treatment Does Not Impair Anti-Tumor Cytokine/Chemokine Induction

Despite being less toxic, Decoy therapeutics induce similar amounts of anti-tumor cytokines and chemokines, uncoupling toxicity from anti-tumor activity

Secretion by Human PBMCs* <i>In Vitro</i>	Untreated Bacteria	Decoy Therapeutic (Decoy10)	Decoy Therapeutic (Decoy20)
Anti-Tumor Cytokine	pg/mL (mean of triplicate determinations ± %CV at same bacterial dose for each cytokine)		
GM-CSF	1,094 ± 22	1,197 ± 2	1,695 ± 23
IFN γ	175,866 ± 7	47,488 ± 3	55,321 ± 10
IL-12p70	176 ± 14	528 ± 7	428 ± 37
TNF α	49,782 ± 11	77,919 ± 13	99,247 ± 16

*Peripheral Blood Mononuclear Cells


Decoy therapeutics are more broadly active than mono-specific TLR agonists

Secretion by Human PBMCs <i>In Vitro</i>	CpG (TLR9)	Poly(I:C) (TLR3)	R848 (TLR7/8)	LPS (TLR4)	Decoy10* (TLR2,4,5,9)
Anti-Tumor Cytokine	pg/mL (triplicate full titration peak average from two exp)				
GM-CSF	0	2	136	27	1,246
IFN γ	7	248	61,914	33,293	171,284
IL-12p70	4	15	205	84	375
TNF α	65	334	36,663	24,944	73,069
MIP-1 α **	0	272	17,866	19,278	29,942


*Decoy therapy tested at doses therapeutically relevant for *in vivo* models

**From one experiment

Single Agent Activity - Metastatic Mouse Pancreatic Carcinoma





Single Agent Activity - Orthotopic Mouse Colorectal Carcinoma





Decoy Synergizes With a Non-Steroidal Anti-Inflammatory Drug (NSAID) to Safely Eradicate Subcutaneous Mouse Hepatocellular Carcinomas (HCC)


Treat 6 mice per group with Decoy 2x per week i.v. for 7 weeks / Start treatment at 103 mm³



NSAIDS reduce myeloid-derived immune suppressive cells




Combination With Anti-PD-1 Checkpoint Therapy Produces 100% Complete Responses With Hepatocellular Carcinoma



* Max % transient weight loss each week for combo treatment
No increase in toxicity with triple combo

Synergistic Eradication of Murine HCC Exhibits a Very Wide Decoy Therapeutic Index (≥ 33 -fold)

All animals also received a non-steroidal anti-inflammatory drug (NSAID)




Start treatment
at ~200 mm³

*Maximum transient body weight loss relative to start of treatment


Mice Cured by Decoy + NSAID + Anti-PD-1 and Re-Challenged with Fresh HCC Tumor Cells Reject the Tumors (Immunological Memory)

Eleven Cured Mice were Re-Challenged with Fresh HCC Tumor Cells on Day 91 on the Opposite Flank from the First Challenge




*All 1st challenge tumor sites remained tumor-free

Six Naïve Mice were Challenged with the Same Tumor Cells as the Cured Mice on the Same Day




Decoy Produces Similar Results in Multiple Mouse Models

Decoy Therapeutic Synergizes with Low-Dose Chemotherapy (LDC) to Safely Induce Regression of s.c. Mouse Non-Hodgkin's-Lymphoma (NHL)




Mice Cured by Decoy + LDC and Re-Challenged with Fresh NHL Tumor Cells Reject the Tumors (Immunological Memory)





*Immunological memory also seen with innate-only human tumor xenograft model

Decoy Technology Also Regresses Human Tumor Xenografts



Decoy Technology can Induce Immunological Memory Via the Innate Immune System



- Tumor regression with immunological memory via the innate immune system alone is very rare in preclinical models, but consistent with a multiple danger signal mechanism
- Results suggest that Decoy technology may synergize with other marketed ADCC mechanism-based, targeted antibody therapeutics (~12 on market)

Decoy Technology Platform

Potential utility as anti-viral therapy - Hepatitis B Virus (HBV), HIV and Others

- HBV is a chronic liver infection affecting 257 million people world-wide
 - Only 2% treated with current therapies / Major cause of cirrhosis and HCC / 887,000 deaths per year
- Cytokines have strong anti-viral activity, but single, oral TLR agonists have failed in the clinic
- Multi-TLR agonist Decoy therapy is passively targeted to liver and safely induce many cytokines
- Standard pre-clinical AAV-HBV mouse model of chronic HBV carried out twice:

Decoy Therapeutic Produces Broader Anti-HBV Activity Than Standard of Care Reverse Transcriptase Inhibitor Entecavir

Inhibition (including for up to 6 months after cessation of treatment)							
	HBV Replication		HBs Antigen		HBe Antigen	HBV ssDNA	cccDNA-Like Molecule
	Plasma	Liver	Plasma	Liver	Plasma	Liver	Liver
Entecavir	✓						
Decoy Therapeutic	✓	✓	✓	✓	✓	✓	✓

Indaptus Clinical Development Plan

	2021		2022		2023		2024		2025	
	Q1/2	Q3/4	Q1/2	Q3/4	Q1/2	Q3/4	Q1/2	Q3/4	Q1/2	Q3/4
Dose Escalation	IND Filing									

Key Milestones

- 1) Determine MTD / Recommended Ph2 dose / Possible efficacy
- 2) Single agent efficacy
- 3) Combination efficacy

Preparations Underway for IND Filing (expected 2H 2021)

- Completed US FDA Pre-IND Meeting
- 28-day Rabbit toxicology - Completed
- Decoy20 GMP batch - Released
- 6-month stability studies with Decoy20 GMP batch - Completed
- Preliminary IND preparation underway
- Preliminary CRO planning underway

Target Indications Include 6 of the World's 12 Deadliest Cancers

12 Deadliest Cancers World-Wide (Decoy Targets)			
		% of Yearly Deaths	% of Yearly Cases
1	Lung	18.4	11.6
2	Colorectal	9.0	10.0
3	Stomach	8.2	5.7
4	Liver	8.2	4.7
5	Breast	6.6	11.6
6	Esophagus	5.3	3.2
7	Pancreas	4.5	2.5
8	Prostate	3.8	7.1
9	Cervical	3.3	3.2
10	Leukemia	3.2	2.4
11	N-H Lymphoma	2.6	2.8
12	Bladder	2.1	3.0
Decoy Indications % of Total		29.7%	26.2%

Source: CA CANCER J CLIN 2018;68:394-424

High Unmet Medical Need

Percent five-year survival
for patients with metastatic disease

3% - 17%

Source: American Cancer Society

Experienced Management and Board of Directors

Leadership experience in new modalities and early development

Roger J. Pomerantz, M.D.	Chairman	   
Michael J. Newman, Ph.D.	Founder, CSO, Director	  
Jeffrey Meckler	CEO, Director	    
Anthony J. Maddaluna	Director	 
W. Brad Hayes	Director	  
Brian O'Callaghan	Director	    
Hila Karah	Director	  
Hoonmo Lee	Director	 

Thank you.


Appendix

There are No Intrinsically “Bad” Cytokines/Chemokines Good or Bad Depends on Time, Place, Amount and How Long

Cytokines and Chemokines Inducing Migration, Activation, Maturation and/or Proliferation	Responsive Immune Cell Type: All Participate in Anti-Tumor Immune Responses
GM-CSF, IL-1 β , IL-4, IL-12, IL-15, IFN- γ	Dendritic Cells
IL-2, IL-12, IL-18, TNF- α	Gamma-Delta ($\gamma\delta$) T-Cells
IL-1 β , IL-8, IFN- γ , MIP-1 α , TNF- α	M1 Macrophage
IL-2, IL-10, IL-12, IL-15, IL-18, IL-21, IFN- γ	NK Cells
IL-12, IL-18, IL-21, IFN- γ	NKT Cells
GM-CSF, IFN- α , IL-4, IL-8, MIP-1 α , TNF- α	Neutrophils
GM-CSF, IL-1 β , IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-15, IL-17, IL-18, IL-21, IFN- γ , MIP-1 α , TNF- α , TNF- β	T-Cells (Th1, Th17 or Th2 CD4+ or CD8+) Including CIK, CTL, LAK


How Can Bacterial Danger Signals Activate Anti-Tumor Immunity?

Most Steps Required for Innate and Adaptive Cellular Immune Responses are Non-Specific



All non-specific steps are induced or promoted by immune system “danger signal” molecules, which also enhance specific (tumor antigen recognition) steps / also many steps don’t occur in the tumor

Toll-Like Receptor (TLR) Agonists from Bacteria Directly Activate Immune Cells and Indirectly Activate by Inducing Secretion of Cytokines and Chemokines




Immune cells can kill tumor or virus-infected cells or inhibit viral infection via cytokine secretion, cytotoxic granules, apoptosis, antibody-dependent cellular cytotoxicity (ADCC) and reactive oxygen/nitrogen species (RO/NS)

Patented Decoy Treatment Kills Bacteria and Significantly Reduces LPS-Endotoxin Activity and *In Vivo* Pyrogenicity

Treatment	Live Bacteria	LPS Endotoxin Activity (LAL Assay)	Pyrogenicity Threshold (Rabbit Assay)
No Treatment	100%	44.7 Units / 10^6 Bacteria	3×10^4 Bacteria
Decoy	0	3.6 Units / 10^6 Bacteria	9×10^5 Bacteria
Change induced by treatment	Killed all bacteria	92% reduction	97% reduction (requires more bacteria to increase rabbit temperature)


Decoy therapeutics are also 100 to 2,500-fold less toxic in mice (LD_{50}) than live, attenuated bacterial products

Decoy Therapeutic Synergizes with Human PBMCs to Kill Human Breast Carcinoma Cells *In Vitro*



Killed, non-pathogenic Decoy therapeutic is not intrinsically toxic to tumor cells (broad dose-response not shown), but can activate immune cells to kill tumor cells


Tumor-Eradicating Combinations Transform “Cold” HCC Tumors to “Hot”



Systemic Administration of Decoy Therapy, NSAID and Anti-PD-1 Induces **Cytokine** Immune Pathways in HCC Tumors

NanoString 770 gene
expression analysis:
Cytokines and
Receptors in tumor


Mice with 200 mm³
tumors were treated
for 1 week before
tumor removal and
RNA isolation/analysis



Systemic Administration of Decoy Therapy, NSAID and Anti-PD-1 Induces **Chemokine** Immune Pathways in HCC Tumors

NanoString 770 gene
expression analysis:
Chemokines and
Receptors in tumor


Mice with 200 mm³
tumors were treated
for 1 week before
tumor removal and
RNA isolation/analysis



Systemic Administration of Decoy Therapy, NSAID and Anti-PD-1 Induces **Innate** Immune Pathways in HCC Tumors

NanoString 770 gene expression analysis: Innate Immune response in tumor


Mice with 200 mm³ tumors were treated for 1 week before tumor removal and RNA isolation/analysis




Systemic Administration of Decoy Therapy, NSAID and Anti-PD-1 Induces **Adaptive** Immune Pathways in HCC Tumors

NanoString 770 gene
expression analysis:
Adaptive Immune
response in tumor

Mice with 200 mm³
tumors were treated
for 1 week before
tumor removal and
RNA isolation/analysis




NHL Tumors That Regrow After 1 or 2 Weeks of Sub-Optimal Decoy + LDC Treatment are Sensitive to Optimal Retreatment



Suggests no or low neutralizing antibody resistance / Very large tumors can be eradicated!

High Percentage Eradication of s.c. NHL by Decoy + LDC Requires NK Cells and CD4+ and CD8+ T Cells


Treat all groups (6 mice per group) with i.v. Decoy + LDC for 2 weeks / Start treatment at ~200 mm³



Frequently Asked Question

- Q) **Humans are more sensitive than mice to the toxic effects of TLR agonists such as LPS. Does this mean that the Decoy product will be too toxic in humans?**
- A) Humans are also more sensitive than mice to anti-tumor cytokine induction by TLR agonists, so if there is a therapeutic index in mice, there may also be one in humans (see next slide).

Decoy Therapy Induces Human PBMCs to Secrete ~100 to 3,500 Times Higher Levels of Anti-Tumor Cytokines Compared to Mouse PBMCs



This is probably why humans are more “sensitive” than mice to TLR agonists and why we will require correspondingly lower doses of Decoy therapy in humans for anti-tumor activity, preserving or possibly increasing the therapeutic index

Different sensitivity to TLRs by mouse and human PBMCs has been reported (Warren J. Infect. Dis. 201 223 2010)